Original Research
Original Research
Lumateperone as Adjunctive Therapy in MDD: A Randomized, Double-Blind, Phase 3 Trial
August 25, 2025
In patients with MDD with inadequate antidepressant response, adjunctive lumateperone 42 mg significantly improved depression symptoms and severity versus adjunctive placebo, and it was generally well tolerated.
Original Research
Levomilnacipran, but Not Duloxetine, Inhibits Serotonin and Norepinephrine Reuptake Throughout Its Therapeutic Range
August 25, 2025
Levomilnacipran and duloxetine are both potent serotonin reuptake inhibitors at all therapeutic regimens for MDD. Potent norepinephrine reuptake inhibition can be achieved from initiation with levomilnacipran, in contrast to...
Original Research
Effect of Aripiprazole or rTMS Augmentation Versus Switching to Venlafaxine on Quality of Life
August 11, 2025
Augmentation with aripiprazole, but not rTMS, improved quality of life significantly versus venlafaxine XR/duloxetine switch in patients with treatment-resistant depression.
Original Research
The Characteristics and Burden of Cognitive Impairments in Schizophrenia in the US
August 11, 2025
Medical Expenditure Panel Survey data showed that over half of adults with schizophrenia report cognitive impairments, which were associated with higher healthcare costs and lower quality of life.
Original Research
Onfasprodil (MIJ821) in Patients with Treatment-Resistant Depression: A Phase 2, Randomized, Placebo-Controlled, Proof-of-Concept Study
August 6, 2025
Onfasprodil appeared to be effective and well-tolerated across all dosing regimens in patients with TRD and demonstrated rapid onset of action (24 hours) with evidence of antidepressant effects to...
Original Research
Effects of Alcohol Use on Cognition in Individuals With Neurocognitive Disorders
August 6, 2025
In a memory clinic cohort of patients with neurocognitive disorders, alcohol related cognitive impairment resulted in specific deficits involving cognitive control during delayed recall task.
Original Research
Long-Term Outcomes of IV Ketamine and IN Esketamine in Treatment-Refractory Depression
July 30, 2025
The study results suggest that patients with treatment-resistant depression who are on maintenance treatment require less frequent treatments with IV ketamine compared to IN esketamine.
Original Research
Early Change in Depressive Symptom Severity with Naltrexone-Bupropion Combination and Its Association with Reduction in Methamphetamine Use: ADAPT-2 Trial
July 30, 2025
Improvement in depression accounted for approximately 25% of the treatment effect of naltrexone-bupropion on methamphetamine treatment response.
Original Research
Klotho and Matrix Metalloproteinase-9 Levels and Their Association with Inhibitory Dyscontrol in Adolescents with First-Episode Major Affective Disorders
July 16, 2025
Adolescents with bipolar disorder and those with MDD had significantly lower Klotho levels compared with the control group; those with bipolar disorder had the highest MMP-9 levels, followed by...
Original Research
Actigraphy-Measured Sleep/Wake Characteristics Associated With Suicidal Ideation in Older Adults With Depression and High Suicide Risk
July 14, 2025
Measures of sleep/wake rhythm disruption were independently associated with higher level of suicidal ideation in this sample of older adults at high risk for suicide.
Original Research
Predictors of Treatment Response to Adjunctive VNS Therapy in Major Depressive Disorder: A RECOVER Trial Report
July 14, 2025
History of ECT use (lifetime and current episode) or TMS use (current episode) was prognostic of poorer outcomes across the total sample and superior benefit from active versus sham...
Original Research
Global Population-Based Study on the Association Between Ketamine and Esketamine with Suicidality Using WHO VigiBase
July 7, 2025
The results do not provide causal evidence of worsening suicidality in persons receiving esketamine/ketamine; mixed results of increased and decreased risk of suicidality were reported with both agents.
Original Research
Differentiating Subtypes of MDD Using Serum Biomarkers
June 23, 2025
Significant differences in biomarker profiles were observed across MDD subtypes: the melancholic subtype showed higher cortisol levels and lower serotonin levels, and the atypical subtype showed elevated levels of...
Original Research
Bright Light Therapy in the Morning or Midday for Nonseasonal Depression in Bipolar Disorder
June 23, 2025
Bright light therapy is well tolerated in bipolar disorder, starting at 45 minutes/day, with only 6% of patients experiencing a hypomanic switch and 13% experiencing subsyndromic symptoms, which resolved...
